OSAKA (Kyodo) Takeda Pharmaceutical Co. and South Korea’s LG Life Science Ltd. said Friday they have agreed to collaborate on the research and development of drugs to fight obesity.

The deal grants Takeda rights to turn chemical compounds developed by LG Life into pharmaceutical products for sale around the world except for South Korea and Vietnam, according to the two drugmakers.

The Japanese company says it might pay royalties worth more than $100 million to its partner in the process.

Takeda focuses on the production of drugs to treat diabetics and patients suffering from high blood pressure, high cholesterol and arteriosclerosis.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.